Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 8/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 7/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10632380 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL9156558 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL3628423 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL24145144 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL10632662 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL23922253 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL8649276 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL7549663 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL10632388 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL9155913 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10NR3C1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321330-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | Universität Hamburg (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010015245-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITÄT HAMBURG (DE) | 2010-02-11 | — | — | WO | disclosed |
| US-20100016250-A1 | TOLL-LIKE RECEPTOR 9 AGONISTS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2017281-A1 | TOLL-LIKE RECEPTOR 9 AGONISTS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-0553297-B1 | PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS | DU PONT (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1992009612-A1 | PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
| US-5095123-A | Phosphorylation | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016250-A1 | TOLL-LIKE RECEPTOR 9 AGONISTS | TLR9, TLR1, TLR7 | CYP2D6 2744/4885THRB 962/4885HSD17B10 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.